Track market-moving stories before they get noisy

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigatge potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Azenta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/azenta-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On August 24, 2026, Azenta filed with the SEC a current report on Form 8-K which stated that on “August 22, 2026, John P. Marotta resigned as President and Chief Executive Officer of Azenta, Inc. (the “Company”) and as a member of the Company’s Board of Directors (the “Board”), effective as of August 22, 2026 (the “Effective Date”).”

On this news, Azenta’s stock fell 12% on August 24, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

by Todd Bishop on

Amazon Bee’s recording light is easy to miss, says a former AWS security engineer. (Amazon Image) Amazon’s new Bee AI devices ask the wrong person for consent, according to a privacy and security veteran who previously worked as a senior principal security engineer at Amazon Web Services.

In a LinkedIn article, Jeff Williams writes that Bee’s consent safeguards are aimed at the wearer, while the people being recorded have no practical way to say no.

Amazon unveiled the devices Thursday, the first new Bee hardware since it acquired the San Francisco startup last year. The $74.99 Bee Frontier goes on the wrist or clips to clothing, and the $99.99 Bee Eclipse snaps onto the back of a phone.

Both turn conversations into summaries and to-do lists, with connections to Amazon.com and Alexa+ for paid subscribers.

How Bee handles consent: Amazon says users are prompted to get permission from call participants each time they start a recording, and the devices show an indicator light while in use.

The problem, Williams says, is that neither one reliably tells the other people in a conversation that they’re being recorded. He writes that the prompt appears only on the wearer’s phone, and nothing enforces it.

“A prompt instructing the user to obtain permission is a liability allocation,” he wrote, arguing that Amazon is shifting responsibility for obtaining consent onto the wearer.

The light is easy to hide under a sleeve or in a pocket, he notes, and a device on the wrist or phone sits outside the frame on a video call.

Williams points to Meta’s Ray-Ban glasses as an example. In September, the data protection authority in Hamburg, Germany, found the glasses’ recording light hard to see outdoors and concluded that a recording indicator alone doesn’t establish informed consent under Europe’s GDPR.

In the U.S., about a dozen states, including Washington state and California, generally require consent from everyone before a private conversation can be recorded.

Whose data is protected: Williams gives Amazon credit for Bee Private Compute, which processes audio in an isolated, encrypted environment built on AWS Nitro and then deletes it. Amazon says only the customer can access the resulting data, not Amazon or Bee.

But that protects the wearer. The words of the people around the wearer still end up in transcripts and summaries they can’t see or remove. Amazon says those speakers aren’t identified by name unless they complete a voice training exercise with the device’s owner.

Williams notes that Amazon has changed comparable privacy commitments before, such as ending the “Do Not Send Voice Recordings” option on some Echo devices last year.

Williams also advises companies to keep the devices out of client meetings and privileged discussions, since the transcripts end up in an employee’s personal account, where the company can’t see or manage them.

A proposed fix: Williams says Bee should leave other people’s voices out of transcripts by default, unless they’ve enrolled their voices and agreed to be recorded. Before the acquisition, Bee indicated plans to record only the voices of people who had verbally consented, according to TechCrunch.

“I know first-hand that Amazon has the engineering talent to ship it,” he wrote.

Amazon’s response: The company didn’t comment directly on the critique but pointed to safeguards built into the devices.

One is an automatic shutoff: the devices turn off if they don’t detect the owner’s voice for 5, 15, 30 or 60 minutes, depending on the user’s setting. Amazon says that reinforces that Bee is “a personal AI assistant, not a device designed to passively pick up audio throughout the day.”

The company says it educates customers about responsible use in the Bee app, and that Eclipse will send push notifications encouraging users to let people around them know they’re using Bee and to ask for permission.

Williams, now chief information security officer at Sigma360, worked at AWS from 2023 to 2025 and spent more than 12 years at Microsoft before that, including as a privacy officer for its services business. Read his full article on LinkedIn. Read his full article on LinkedIn.

SAN JOSE, Calif. & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, welcomes the decision of the Unified Patent Court (“UPC”) finding that aligner systems incorporating Angelalign’s Torque Ridges feature infringe Align’s European Patent EP 2 237 738 B1, which relates to Align’s Power Ridge® technology.

In August 2025, Align initiated patent infringement proceedings against several companies within the Angelalign Technology, Inc. corporate group (“Angel”) (Hong Kong Stock Exchange: 6699.HK) in multiple jurisdictions, including before the UPC, which covers participating European Union member states.

On October 16, 2026, the Paris Local Division of the UPC ruled that aligner systems incorporating Angel’s Torque Ridges feature infringe Align’s patent. The Court rejected Angel’s challenges to the validity of the patent, issued an injunction requiring Angel to recall and destroy infringing products, ordered Angel to pay damages to Align, and granted Align other relief. Angel must cease offering infringing aligner systems incorporating Torque Ridges in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Slovenia, and Sweden. The decision is subject to appeal.

Commenting on the UPC decision, Arthur S. Hsieh, Align Technology vice president, Deputy General Counsel, Intellectual Property & Licensing, said, “The ruling represents a significant victory for Align and underscores the importance of protecting the innovations resulting from Align’s substantial and sustained investment in research and development. Angel has sought to downplay the impact of the ruling by emphasizing that Angel recently discontinued Torque Ridges in Europe and introduced a different feature called ‘Pressure Points.’ This should not obscure the significance of the Court’s decision: Angel’s Torque Ridges were found to infringe Align’s patented technology, and Angel has publicly stated that it will comply with the Court’s ruling, which requires Angel to recall and destroy infringing products, pay damages to Align, and take other remedial actions. Similarly, Angel’s characterization of Pressure Points as an “upgrade” or “next generation” of Torque Ridges should not be understood to establish that the two technologies are technically equivalent or that Pressure Points provide an equivalent alternative to Torque Ridges. Angel’s own public materials describe Pressure Points as based on the longstanding use of “hand-made dimples” to apply targeted forces to teeth. Align does not view Angel’s Pressure Points as a technological upgrade to, or an equivalent replacement for, the ridge-based technology at issue in the UPC proceeding.”

Align’s Power Ridge® technology is designed to apply targeted forces to improve root torque control and support predictable tooth movement. The Power Ridge feature remains available as an integral part of the Invisalign® System, providing doctors with differentiated technology to support high-quality patient care.

Align has not taken a public position on whether Angel’s Pressure Points implicate Align’s intellectual property rights. Align will continue to evaluate products and technologies offered by Angel and other market participants and will take appropriate action when necessary to protect its innovations and intellectual property.

The October 16 decision follows other recent developments in Align’s global patent enforcement actions against Angel. In February 2026, the UPC issued a preliminary injunction requiring Angel to cease infringement of Align’s patented ClinCheck® Live Update technology. That decision was subsequently upheld by the UPC Court of Appeal, and proceedings on the merits remain ongoing. In July 2026, the U.S. International Trade Commission (“ITC”) conducted an evidentiary hearing concerning five patents asserted by Align against Angel. Align expects an initial determination regarding the merits of its claims in November 2026. In August 2026, the Jinan Intermediate People's Court in China issued a first-instance judgment finding that Angel's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringes Align's patent rights. The court further found that aligner products manufactured and sold using the accused technology also infringe. Angel has appealed the Jinan Court’s decision. Align continues to pursue additional patent infringement actions against Angel in China.

Align remains committed to advancing orthodontic treatment through differentiated technologies backed by decades of research, engineering, clinical experience, and investment, and to vigorously protecting the intellectual property underlying those innovations.

Align’s Cutting-Edge Global Operations

As a global leader in digital orthodontics and restorative dentistry with nearly 23.5 million Invisalign® patients treated worldwide, Align continues to transform the orthodontic industry through its global operations, advanced manufacturing capabilities, and doctor-directed treatment planning. Annually, Align invests over $300M in technology to give patients of all ages access to the smiles they want and deserve through Invisalign-trained doctors.

Align’s operations span the Americas, EMEA, and APAC regions, with clinical treatment planning centers in Costa Rica, Poland, China (Chengdu), Spain, France, Germany, and Japan. The company’s global aligner manufacturing operations includes world-class facilities in Juarez, Mexico; Wroclaw, Poland; and Ziyang, China; Vienna, Austria; San Jose, CA; and a new aligner manufacturing facility coming online in 2027 in Hyderabad, India, together forming the backbone of the world’s largest 3D printing network for dental aligners (appliances).

Align’s investments in global operations are designed to bring its facilities closer to doctor-customers and their patients. In Mexico, the Juarez facility serves as a strategic node in Align’s global supply chain, enabling fast and cost-effective delivery of aligners to customers in the U.S., Canada, Latin America, and beyond. In China, the Chengdu treatment planning center and Ziyang manufacturing facility are central to Align’s long-term investment strategy for China, supporting the local economy and one of its fastest-growing markets by helping Chinese doctors provide millions of Chinese consumers access to high-quality orthodontic care. Wroclaw, Poland is the operations hub for Align’s EMEA business, bringing operations and support closer to the more than 63,000 Invisalign-trained doctors in the region.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 302.0 thousand doctor-customers and are key to accessing Align’s 600-million-consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 23.5 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and labs/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

More News From Align Technology, Inc.

In August 1994, Berkshire Hathaway (BRKA +1.08%)(BRKB +1.21%) ended a seven-year buying spree in Coca-Cola (KO +2.06%). All told, Warren Buffett spent about $1.3 billion on what are now 400 million shares of the drinks giant.

And Berkshire still owned all of those shares at the end of June, according to its last quarterly filing. With Coca-Cola stock at around $93 as I write, near its record high, the stake is worth about $37 billion.

Even more impressive, Berkshire now gets about $848 million a year in Coca-Cola dividends. That's about 65% of what it originally spent on the shares, every single year.

Could someone buying the stock near today's record expect anything similar? I doubt it. And I think the reason has more to do with the price Buffett paid than with the business he bought.

Warren Buffett and Bill Gates. Image source: Getty Images.

Bigger dividend checksBuffett laid out why this investment did so well in Berkshire's 2022 shareholder letter.

"All Charlie [Munger] and I were required to do was cash Coke's quarterly dividend checks," he wrote, after noting Berkshire's yearly dividend from Coca-Cola had climbed from $75 million in 1994 to $704 million in 2022.

The checks kept getting bigger from there. Berkshire took in $816 million in Coca-Cola dividends in 2025, according to the conglomerate's latest annual letter. In February, Coca-Cola boosted its quarterly dividend around 4% to $0.53 a share, its 64th consecutive annual increase. On Berkshire's 400 million shares, the new rate means around $848 million a year. The 1994 check has grown more than elevenfold.

But the growth has slowed. Between 1994 and 2022, Berkshire's Coca-Cola dividends compounded at around 8% yearly. The rise from $704 million to the current $848 million rate means growth closer to 5% a year.

Buffett bought a far higher yieldThe pace of raises counts, but so does the starting point. Berkshire's $75 million in dividends in 1994 was around 5.8% of what it paid for the shares. In other words, Buffett was already getting a solid yield the year Berkshire finished buying, before three decades of raises were added to it.

I'd say that starting yield did as much of the work as the raises did.

A buyer today starts from a much lower base. At around $93, Coca-Cola's $2.12 yearly dividend comes to a yield of about 2.3%. Put the same $1.3 billion into the stock today, and it'd pay about $30 million a year in dividends, under half of what Berkshire got in 1994.

Even if Coca-Cola keeps raising its payout about 5% a year, a buyer at today's price would need almost two decades to earn a 5.8% yield on what they paid.

Is Coca-Cola stock a buy near a record high?Sure, Coca-Cola's business is doing well. Showing its momentum, the company grew organic revenue (sales growth excluding currency moves, acquisitions, and divestitures) 6% for the second quarter of 2026 versus the same period last year.

On a non-GAAP (adjusted) basis, earnings per share climbed 11% year over year, and 14% in the year's first six months. And management now expects adjusted earnings per share to grow 9% to 10% in 2026, helped by currency. That suggests slower growth in the second half than in the first.

But the stock has arguably run ahead of that growth. Coca-Cola shares have risen around 34% since 2025 ended, adding more than $9 billion to the value of Berkshire's stake.

$93.90+$1.90 (+2.06%)

NYSE · As of 4:00 PM ET 10/16/26

At about 29 times its adjusted earnings for the last four quarters, Coca-Cola stock costs much more than the 23 times earnings it fetched at the end of 2025. Based on next year's expected earnings, its price-to-earnings ratio is still around 26.

That's a hefty price for a business expected to grow earnings at a high-single-digit pace. It also means a new buyer might be relying on more than steady dividend growth. They probably need the stock to keep most of this year's higher valuation, too.

In the end, Coca-Cola is still the sort of business Buffett bought. But Berkshire's result came from buying it when the dividend already paid a solid yield, then waiting over 30 years. At around 29 times earnings and a 2.3% yield, a new buyer gets the same business without that starting point.

For investors who already own the stock, holding on looks reasonable to me. But I'd want a higher starting yield than 2.3% before buying in.

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between August 8, 2024 and May 13, 2026, both dates inclusive (the “Class Period”), of the important November 16, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Doximity common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Doximity class action, go to https://rosenlegal.com/cases/doximity-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, Doximity overstated the impact that its Newsfeed would have on its revenue growth, and Doximity was losing market share to its competitors with more favorable pricing and engagement models, while also using banner ads and e-newsletters instead of deep engagement tactics. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Doximity class action, go to https://rosenlegal.com/cases/doximity-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

AAPL Apple$343.46+$1.46 (+0.43%)

NASDAQ · As of 4:00 PM ET 10/16/26

Apple (AAPL +0.43%), a consumer electronics and personal computing hardware provider, closed at $343.46, up 0.43%. The stock edged higher after reports that iPhone Duo preorders sold out quickly, and investors are watching the November 2 earnings call for guidance and demand updates.

Trading volume reached 59 million shares, coming in about 31% above its three-month average of 45 million shares.

How the markets moved todayS&P 500 (SNPINDEX: ^GSPC) closed at 7,659, down 1.09%, while Nasdaq Composite (NASDAQINDEX: ^IXIC) finished at 26,140, down 2.14%. Among consumer electronics and personal computing hardware peers, Microsoft (MSFT -1.93%) closed at $529.05, down 1.93%, and Alphabet (GOOGL -2.47%) closed at $340.59, down 2.47%, as investors kept focus on AI-debt pressure and semiconductor weakness.

What this means for investorsApple shares rose on Friday, Oct. 16, when pre-orders for its new iPhone Duo sold out within minutes in the morning. The Duo is the company's first foldable smartphone. It includes a 5.4-inch front display with a 7.6-inch foldable inner screen. Delivery dates quickly shifted from Oct. 23 into late January.

The strong demand for Apple's latest device propelled its stock back toward the 52-week high of $348.15 reached earlier in the week. In the company's 2026 third quarter, ended June 27, Apple posted record performance as revenue reached $109.4 billion, which represented a 16% year-over-year increase. The iPhone maker beat Wall Street expectations on revenue and profit, but investors focused on strong iPhone 17 demand and a softer near-term outlook that later weighed on sentiment.

With the Duo's preliminary success, Apple could see strong 2027 sales results. The question is how much of a headwind macroeconomic conditions, such as persistent inflation and rising interest rates, will be for the tech giant.

Robert Izquierdo has positions in Alphabet, Apple, and Microsoft. The Motley Fool has positions in and recommends Alphabet, Apple, and Microsoft. The Motley Fool has a disclosure policy.

When investors think about cloud computing, Alphabet (GOOGL -2.47%)(GOOG -2.32%) and Microsoft (MSFT -1.93%) are often the first names that come to mind. But Oracle (ORCL -4.64%) is also making a strong push into AI infrastructure, and its rapidly growing cloud business offers another way to ride the AI boom.

With $5,000 to put to work today, investors may find Oracle a more compelling cloud choice than either of those giants. The reason starts with how fast its cloud business is growing.

Image source: Getty Images.

This database giant is becoming a major force in AI cloud
Oracle may be best known for its database software, which businesses use to store and manage critical information. These days, that established business is laying the foundation for a much bigger opportunity: supplying the cloud infrastructure that other companies need to develop and run AI models.

Oracle's cloud infrastructure business is already seeing solid growth, with revenue climbing 121% to $7.4 billion in its most recent quarter. That suggests its cloud business is becoming an important growth engine rather than simply an extension of its traditional software business.

ORCL Oracle$128.23-$6.24 (-4.64%)

NYSE · As of 4:00 PM ET 10/16/26

Its massive backlog, meanwhile, provides a longer runway for growth. Oracle's remaining performance obligations (RPO) reached a record $664 billion, up $209 billion year over year. RPO represents contracted revenue that has not yet been recognized, giving investors a clearer view of the company's future revenue.

That means Oracle is seeing surging demand from customers that need cloud capacity for AI training, applications, and inference. Still, that demand isn't limited to one type of customer, and Oracle is positioning itself to capture several parts of that market.

But with competition picking up, the next question is how Oracle is setting itself apart from the biggest names in the cloud business.

Oracle has a different advantage from its larger cloud rivals
Microsoft Azure and Alphabet's Google Cloud compete across broad cloud ecosystems. However, Oracle's opportunity is somewhat different: it has the luxury of combining its established database business with cloud infrastructure designed for demanding enterprise workflows.

That matters because companies wouldn't want to rebuild their IT systems every time a new AI model arrives. Oracle's database expertise helps here, allowing companies to integrate AI into the systems and data they already rely on without disrupting operations.

Its multicloud strategy also allows customers to access Oracle database services through major cloud platforms, including Amazon Web Services, Microsoft Azure, and Google Cloud. Instead of requiring customers to migrate everything to Oracle's cloud, it can meet businesses where their existing systems reside.

On top of that, Oracle's established software business provides a source of recurring revenue. Its cloud applications include enterprise resource planning, human resources, and supply chain tools that businesses use to run their daily operations.

That combination of AI-driven growth and recurring software revenue gives the company multiple avenues to expand, which only strengthens the bull case for Oracle.

Still, even a strong bull case needs a reasonable price point and manageable risks.

Is Oracle stock a buy after its recent pullback?
A consensus rating for Oracle among 42 analysts is a strong buy, with target prices indicating between 87% (average) and 206% (highest) upside over the next 12 months. Plus, at about 20 times earnings, Oracle doesn't look too expensive, especially considering its rapid cloud growth.

That said, Oracle is spending heavily to build the data centers needed to serve its customers. And that investment is already weighing on its free cash flow, which means Oracle is spending more than its operations generate. Overspending is a real risk, as the concern is whether Oracle can convert its customer commitments into sufficient revenue to deliver a decent return on those investments.

Looking ahead, if Oracle can turn its massive backlog into lasting profits, today's pullback could be an attractive entry point for long-term investors.

Oracle may not get the same attention as Alphabet or Microsoft, but its growing cloud business and expansion into AI make it worth a closer look. With $5,000, investors can gain meaningful exposure to that opportunity.

AbbVie (ABBV +0.71%), which accounts for 6.2% of my portfolio, is one of my favorite long-term dividend stocks. The pharmaceutical giant has raised its dividend annually for 53 consecutive years, making it a Dividend King that has increased its payout for at least 50 years.

I'm sitting on an unrealized gain of nearly 200% on my original position in AbbVie, which I started in early 2020, and I've consistently reinvested my dividends. Its forward yield of 2.4% might seem low compared to the 10-Year Treasury's 5.1% yield. Still, its low forward price-to-earnings ratio of 16 and its massive portfolio of billion-dollar drugs (including the blockbusters Skyrizi and Rinvoq) should limit its downside potential in this choppy market.

Image source: Getty Images.

How many shares of AbbVie should you own for $5,000 in annual income?
To earn $5,000 in annual dividends from AbbVie, you would need to own 723 shares for about $206,358 as of this writing. That might not seem like a great deal, especially when the same investment in Pfizer (PFE +0.48%) would generate nearly $12,000 in annual dividends.

ABBV AbbVie$285.42+$2.02 (+0.71%)

NYSE · As of 4:00 PM ET 10/16/26

But over the past three years, AbbVie's stock rallied 93% as it overcame its loss of U.S. exclusivity for Humira (its blockbuster autoimmune drug) and expanded its new drugs to offset that pressure. Pfizer's stock sank 8% as its sales of COVID-19 vaccines evaporated and its other major drugs faced patent cliffs. Therefore, AbbVie could still be a solid investment for long-term income investors, even though its yield seems unimpressive.

Leo Sun has positions in AbbVie and Pfizer. The Motley Fool has positions in and recommends AbbVie and Pfizer. The Motley Fool has a disclosure policy.

MercadoLibre (MELI - Free Report) closed at $1,835.36 in the latest trading session, marking a -1.16% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 1.09%. At the same time, the Dow lost 0.34%, and the tech-heavy Nasdaq lost 2.15%.

Coming into today, shares of the operator of an online marketplace and payments system in Latin America had gained 1.74% in the past month. In that same time, the Retail-Wholesale sector gained 3.71%, while the S&P 500 gained 2.44%.

Investors will be eagerly watching for the performance of MercadoLibre in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $9.42, marking a 13.22% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $10.64 billion, reflecting a 43.61% rise from the equivalent quarter last year.

For the full year, the Zacks Consensus Estimates project earnings of $38.13 per share and a revenue of $41.73 billion, demonstrating changes of -3.22% and +44.45%, respectively, from the preceding year.

It's also important for investors to be aware of any recent modifications to analyst estimates for MercadoLibre. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 2.51% downward. MercadoLibre presently features a Zacks Rank of #3 (Hold).

In terms of valuation, MercadoLibre is currently trading at a Forward P/E ratio of 48.7. This indicates a premium in contrast to its industry's Forward P/E of 15.65.

It is also worth noting that MELI currently has a PEG ratio of 1.3. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Internet - Commerce industry currently had an average PEG ratio of 1.25 as of yesterday's close.

The Internet - Commerce industry is part of the Retail-Wholesale sector. Currently, this industry holds a Zacks Industry Rank of 174, positioning it in the bottom 30% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

FMC Corporation sold roughly $403 million of newly issued shares in September 2026 and previously announced a $1.2 billion senior secured notes offering before cutting its Q3 2026 revenue outlook from $840 million to $900 million down to $65 million to $125 million. The investigation focuses on the Company's SEC-reported offering disclosures.

, /PRNewswire/ -- FMC Corporation (NYSE: FMC) shares fell between 31% and 46% after the Company cut its third-quarter 2026 revenue outlook to $65 million to $125 million, down from $840 million to $900 million. That reset came weeks after FMC sold approximately $403 million of newly issued stock at $13.30 per share. If you lost money on FMC stock, you are encouraged to submit your FMC loss details now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

FMC's own SEC filings record the capital raises. A Form 8-K filed May 19, 2026 relates to the Company's secured notes, and FMC marketed approximately $1.95 billion of secured notes across May and June 2026. A Form 8-K filed July 1, 2026 reports the sale of newly issued FMC shares to Tessenderlo Group at $13.30 per share, worth roughly $403 million, the transaction closed on September 23, 2026. The investigation examines the Company's SEC-reported offering disclosures in light of its subsequent Q3 2026 revenue guidance reduction.

The revised outlook calls for a third-quarter Adjusted EBITDA loss of $510 million to $565 million, compared with the previously projected Adjusted EBITDA profit of $120 million to $140 million. Levi & Korsinsky is investigating potential securities law violations tied to the disclosures FMC provided to investors and note purchasers while these offerings were underway.

FMC shareholders who suffered losses can request a free review of their FMC losses or call Joseph E. Levi, Esq. at (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the FMC Investigation

Q: Who is eligible to participate in the FMC investigation?A: Investors who purchased FMC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did FMC stock drop?A: Shares fell approximately 31% to 46% after the Company issued a Form 8-K revising its third-quarter 2026 revenue guidance to $65 million to $125 million, from $840 million to $900 million. The same update moved its Adjusted EBITDA outlook to a loss of $510 million to $565 million. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether FMC Corporation made materially false or misleading statements about its business conditions and outlook.  The focus is on disclosures tied to its May–June 2026 secured notes offerings and its June 30, 2026 agreement to sell newly issued shares to Tessenderlo, which was reported in an SEC Form 8-K filed July 1, 2026. When the Company disclosed its Q3 2026 guidance revision, the stock price declined sharply.

Q: What do FMC investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my FMC shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought FMC and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: What if I live outside the United States?A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP

Signet Jewelers Limited (NYSE:SIG)’s potential involvement in a consortium seeking to acquire De Beers is aligned with its natural diamond strategy, UBS analysts wrote in a note. 

Natural diamonds made up about 40% of Signet’s calendar 2025 sales, according to analysts.  

UBS said the potential investment lines up with the company’s focus on higher price points and more premium brands, such as Blue Nile. 

According to Bloomberg, Richemont and Signet are in advanced talks to join the Global Diamond Consortium, which is led by former De Beers CEO Gareth Penny. The group is seeking to acquire De Beers from Anglo American. A separate Bloomberg report cited a potential valuation of about $1 billion. 

UBS cautioned that the discussions may not lead to a transaction and that neither company’s participation is assured. The analysts noted that three Southern African governments and other private investors are expected to hold significant ownership positions, so Richemont and Signet could ultimately hold relatively small interests. 

The firm said it views potential participation in De Beers mainly through a strategic lens rather than as a meaningful near-term earnings catalyst. 

UBS said it will be watching the size and valuation of Signet’s stake, the associated capital commitment, and whether participation delivers meaningful commercial or supply chain advantages. Until those factors become clearer, the firm does not see the reported discussions as materially changing its earnings outlook or valuation for Signet. 

The firm pointed to initiatives implemented over the last five years to strengthen omnichannel capabilities, improve the jewelry assortment and optimize the supply chain. UBS sees a path to continued EBIT margin recapture over time and forecasts a 13% five-year EPS compound annual growth rate. 

UBS rates Signet a Buy with a $136 price target. 

CENTENNIAL, CO / ACCESS Newswire / October 16, 2026 / NioCorp Developments Ltd. ("NioCorp," "our," or the "Company") (NASDAQ:NB) today provided its preliminary unaudited financial results for the three-month period ended September 30, 2026, which are presented below.

The Company reported net income attributable to NioCorp of $3.7 million, or $0.03 per share (basic), for the three-month period ended September 30, 2026, as compared to a net loss attributable to NioCorp of $42.7 million, or $0.53 per share (basic), for the three months ended September 30, 2025. As of September 30, 2026, the Company had a cash balance of $405.1 million on its consolidated balance sheet.

The net income for the three months ended September 30, 2026, primarily reflects non-cash gains of approximately $8.5 million related to earnout shares and warrants classified as liabilities on the consolidated balance sheet, driven by a decrease in the closing price of the Company's common shares between June 30, 2026 and September 30, 2026. By contrast, the net loss for the three months ended September 30, 2025, primarily reflects non-cash losses of approximately $32.1 million related to earnout shares and warrants classified as liabilities on the consolidated balance sheet, driven by an increase in the closing price of the Company's common shares between June 30, 2025 and September 30, 2025.

The Company continues as a development-stage company, and its operating cash outflows for the three-month period ended September 30, 2026, totaled $6.1 million, primarily representing recurring general and administrative costs as well as costs related to the finalization and issuance of the technical and economic study related to the Elk Creek Critical Minerals Project (the "Elk Creek Project"). In addition, its investing outflows for the three-month period ended September 30, 2026, totaled $5.9 million, primarily representing additional expenditures associated with ongoing construction of the mine portal at the Elk Creek Project.

NioCorp intends to file its unaudited interim condensed consolidated financial statements for the three-month period ended September 30, 2026, in its Quarterly Report on Form 10-Q on or before November 16, 2026.

All figures reported above with respect to the three- month period ended September 30, 2026, are preliminary and are unaudited and subject to change and adjustment as the Company prepares its unaudited interim condensed consolidated financial statements for the three- month period ended September 30, 2026 and 2025. Accordingly, investors are cautioned not to place undue reliance on the foregoing information. The Company does not intend to provide preliminary results on a regular basis in the future. The preliminary results provided in this news release constitute "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws, are based on several assumptions and are subject to a number of risks and uncertainties. Actual results may differ materially. See "Forward-looking Statements."

# # #

FOR MORE INFORMATION:

Jim Sims, Chief Communications Officer, NioCorp Developments Ltd., (720) 334-7066, [email protected]

Alex Guthrie, Director, Investor Relations, NioCorp Developments Ltd., (647) 999-0527, [email protected]

@NioCorp $NB #Niobium #Scandium #rareearth #neodymium #dysprosium #terbium #ElkCreek

ABOUT NIOCORP

NioCorp is developing the Elk Creek Project that is expected to produce niobium, scandium, titanium and several rare earth products, including neodymium-praseodymium oxide, dysprosium oxide, terbium oxide, samarium-europium-gadolinium ("SEG") carbonate, and heavy rare earth carbonate. Niobium is used to produce specialty alloys as well as High Strength, Low Alloy steel, which is a lighter, stronger steel used in automotive, structural, and pipeline applications. Scandium is a specialty metal that can be combined with Aluminum to make alloys with increased strength and improved corrosion resistance. Scandium is also a critical component of advanced solid oxide fuel cells. Titanium is used in various lightweight alloys and is a key component of pigments used in paper, paint and plastics and is also used for aerospace applications, armor, and medical implants. Magnetic rare earths, such as neodymium, praseodymium, terbium, and dysprosium are critical to the making of neodymium-iron-boron magnets, which are used across a wide variety of defense and civilian applications.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of applicable Canadian securities laws (collectively "forward-looking statements"). Forward-looking statements may include statements regarding, among other matters, the financial and business performance of NioCorp; NioCorp's anticipated results and developments in the operations of NioCorp in future periods; NioCorp's planned exploration and development activities; the adequacy of NioCorp's financial resources; NioCorp's ability to secure sufficient project financing to complete construction and commence operation of the Company's niobium, scandium, titanium and rare earth project (the "Elk Creek Project") located in southeastern Nebraska; NioCorp's expectations on the form of future project financing; the necessity and impact of additional binding offtake agreements and the terms of such agreements, if any; NioCorp's ability to receive a final commitment of financing from the Export-Import Bank of the United States ("EXIM"); future standards imposed by the U.S. federal government, if any; the estimated total upfront capital expenditure for the Elk Creek Project; NioCorp's expectation and ability to produce niobium, scandium, titanium and the rare earth elements at the Elk Creek Project; NioCorp's plans to produce and supply specific products and market demand for those products; NioCorp's expectation that it will receive the full $10.0 million in reimbursement under the DoW Agreement; the intended use of our cash balance as of September 30, 2026, the proceeds from Warrant exercise issuances, and the reimbursement payments pursuant to the DoW Agreement; the Elk Creek Project's ability to produce multiple critical metals; the Elk Creek Project's projected ore production and mining operations over its expected mine life; statements with respect to the estimation of mineral resources and mineral reserves; statements with respect to projected product pricing, costs, and project economics; the exercise of options to purchase additional land parcels; the execution of contracts with engineering, procurement and construction companies; NioCorp's possible future usage of artificial intelligence ("AI") and the risks and challenges associated therewith; NioCorp's ongoing evaluation of the impact of inflation, supply chain issues, tariffs, and geopolitical unrest on the Elk Creek Project's economic model; construction of the main access to the underground portion (the "Portal Project") of the Elk Creek Project; and the creation of full time and contract construction jobs over the construction period of the Elk Creek Project.

Forward-looking statements are frequently, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potential," "possible," and similar expressions, or statements that events, conditions, or results "will," "may," "could," or "should" (or the negative and grammatical variations of any of these terms) occur or be achieved. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect," "is expected," "anticipates" or "does not anticipate," "plans," "estimates," or "intends," or stating that certain actions, events, or results "may," "could," "would," "might," or "will" be taken, occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements reflect material expectations and assumptions, including, without limitation, expectations and assumptions relating to: NioCorp's ability to receive sufficient project financing for the construction of the Elk Creek Project on acceptable terms, or at all; the future price of and demand for metals, including Al-Sc alloy; the impact that Chinese restrictions have on pricing and demand including the existence of a bifurcated market between China and the rest of the world; and the stability of the financial and capital markets. Such forward-looking statements reflect the Company's current views with respect to future events and are subject to certain known and unknown risks, uncertainties, and assumptions. Many factors could cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others, risks related to the following: NioCorp's requirement of significant additional capital; NioCorp's ability to receive sufficient project financing for the construction of the Elk Creek Project on acceptable terms, or at all; NioCorp's ability to achieve the required milestones and receive the full $10.0 million in reimbursement under the DoW Agreement; NioCorp's ability to receive a final commitment of financing from EXIM or other debt financing or financial support on acceptable timelines, on acceptable terms, or at all; NioCorp's ability to continue to meet Nasdaq listing standards; risks relating to the Common Shares, including price volatility, lack of dividend payments and dilution or the perception of the likelihood of any of the foregoing; the extent to which NioCorp's level of indebtedness and/or the terms contained in agreements governing NioCorp's indebtedness, if any, or other agreements may impair NioCorp's ability to obtain additional financing, on acceptable terms, or at all; NioCorp's limited operating history; NioCorp's history of losses; the material weakness in NioCorp's internal control over financial reporting, NioCorp's efforts to remediate such material weakness and the timing of remediation; the possibility that NioCorp may qualify as a "passive foreign investment company ("PFIC") under the Internal Revenue Code of 1986, as amended (the "Code"); the potential that the 2023 business combination with GXII could result in NioCorp becoming subject to materially adverse U.S. federal income tax consequences as a result of the application of Section 7874 and related sections of the Code; changes in tax laws and regulations; cost increases for NioCorp's exploration and, if warranted, development projects; a disruption in, or failure of, NioCorp's information technology systems, including those related to cybersecurity; equipment and supply shortages; variations in the market demand for, and prices of, niobium, scandium, titanium and rare earth products, including, without limitation, a reduction of demand for scandium from a downturn in capital spending for AI; impacts on the markets and pricing for scandium and rare earth products from the Chinese-based markets, including any future changes to export restrictions; current and future offtake agreements, joint ventures, and partnerships, including our ability to negotiate extensions to existing agreements or to enter into new agreements, on favorable terms or at all; NioCorp's ability to negotiate definitive agreements for existing non-binding memoranda of understanding and non-binding term sheets; NioCorp's ability to attract qualified management; estimates of mineral resources and reserves; mineral exploration and production activities; technical and economic study results; the results of metallurgical testing; the results of technological research; unexpected variations in the quantity of ore, grade or recovery rates, or the presence of deleterious elements that would affect the process plant or waste removal; unexpected geotechnical and hydrogeological conditions from what was assumed in the mine designs; changes in demand for and price of commodities (such as fuel and electricity) and currencies; competition in the mining industry; changes or disruptions in the securities markets; legislative, political or economic developments, including changes in federal and/or state laws that may significantly affect the mining and scandium alloy industries; trade policies and tensions, including tariffs and other export controls; inflationary pressures; the impacts of climate change, as well as actions taken or required by governments related to strengthening resilience in the face of potential impacts from climate change; changes in other environmental and social factors; the need to obtain permits and comply with laws and regulations and other regulatory requirements; the timing and reliability of sampling and assay data; the possibility that actual results of work may differ from projections/expectations or may not realize the perceived potential of NioCorp's projects; risks of accidents, equipment breakdowns, and labor disputes or other unanticipated difficulties or interruptions; the possibility of cost overruns or unanticipated expenses in development programs; operating or technical difficulties in connection with exploration, mining, development or scandium alloy production activities; management of the water balance at the Elk Creek Project site; land reclamation requirements related to the Elk Creek Project; the speculative nature of mineral exploration and development, including the risks of diminishing quantities or grades of reserves and resources; claims on the title to NioCorp's properties; the infringement or loss of NioCorp's intellectual property rights; potential future litigation; NioCorp's lack of insurance covering all of NioCorp's operations; and changes in operating and capital costs, exchange rates, metallurgical performance, labor availability and other risks associated with the mining industry.

Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of NioCorp prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

All subsequent written and oral forward-looking statements concerning the matters addressed herein and attributable to NioCorp or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Except to the extent required by applicable law or regulation, NioCorp undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

SOURCE: NioCorp Developments Ltd.

Key Takeaways CBRS shares fell 25.3% in a month amid rising costs and margin pressure.
Cerebras' Q2 core revenues surged 103% on strong AI demand.
CBRS' $25.4 billion backlog supports growth despite margin concerns.

Cerebras (CBRS - Free Report) shares have plunged 25.3% in the past month, underperforming the broader Zacks Business Services sector, which returned 0.3%.

The company’s shares have also underperformed its competitors, which include NVIDIA (NVDA - Free Report) , Advanced Micro Devices (AMD - Free Report) , and Intel (INTC - Free Report) in the AI space. Shares of NVIDIA and Advanced Micro Devices gained 1.6% and 9.7%, respectively, while Intel lost 5.6% over the past month.

The underperformance can be attributed to near-term margin pressure from higher costs associated with renting back systems to expand its cloud capacity. Data center availability constraints and deployment delays could limit revenue growth, while significant investments in manufacturing and infrastructure weigh on profitability. Heavy dependence on OpenAI poses customer concentration risks.

CBRS Stock Performance
Image Source: Zacks Investment Research

However, Cerebras is benefiting from surging demand for high-speed AI inference, expanding cloud deployments and strategic partnerships with hyperscalers. Growing data center capacity, manufacturing expansion and a strong backlog are supporting its long-term growth prospects.

CBRS Benefits From Strong AI Demand and Backlog GrowthCerebras is benefiting from robust demand for artificial intelligence (AI) infrastructure, driven by the rapid adoption of high-speed inference across enterprises, hyperscalers and AI developers. The company’s second-quarter 2026 core revenues surged 103% year over year to $209.9 million, reflecting strong demand for its AI computing solutions. Core cloud and other services revenues jumped 287% to $127.7 million, supported by expanding OpenAI deployments and increased cloud customer usage.

The company is aggressively expanding its data center footprint to capitalize on increasing AI infrastructure investments. The company secured more than 600 megawatts of data center capacity, either operational or under contract for delivery by the end of 2027. Its manufacturing expansion initiatives, supported by partnerships with Flex, Sanmina and TSMC, are expected to increase manufacturing capacity by more than tenfold in 2026. These investments position Cerebras to address growing customer demand and accelerate revenue growth.

Strategic collaborations with OpenAI, Amazon Web Services (AWS) and other hyperscalers further strengthen Cerebras’ growth prospects. Its partnership with OpenAI is supporting strong demand for high-speed AI inference, while AWS integration through Amazon Bedrock, expected to become generally available in the first quarter of 2027, should expand enterprise adoption. Growing customer engagements across AI coding, agentic workflows and cybersecurity provide additional opportunities to diversify its revenue streams.

Cerebras’ strong backlog also supports future upside. Remaining performance obligations stood at $25.4 billion as of June 30, 2026, supporting investments in infrastructure and manufacturing expansion. The company expects core revenues to more than triple in 2027, followed by significant growth in subsequent years. Expanding adoption across AI coding, agentic workflows and cybersecurity applications is expected to strengthen Cerebras’ long-term growth trajectory.

CBRS’ Estimate Revisions Show Improving TrendCerebras robust AI infrastructure demand, expanding capacity, strategic partnerships and strong revenue visibility are expected to benefit the company’s top-line growth. For the third quarter of 2026, Cerebras expects core revenues to be in the range of $214-$216 million.

The Zacks Consensus Estimate for third-quarter 2026 loss is pegged at 13 cents per share, narrower than 32 cents over the past 90 days.

 The consensus estimate for CBRS’ 2026 loss is pegged at 52 cents per share, narrower than a loss of 89 cents per share over the past 90 days.

CBRS Grapples With Rising Costs and Fierce CompetitionDespite CBRS’s expanding AI Infrastructure portfolio, the company is suffering from rising infrastructure investments and near-term margin pressure associated with its aggressive capacity expansion. In the second quarter of 2026, core gross margin declined 590 basis points (bps) sequentially to 40.6% as Cerebras temporarily rented systems back from customers to satisfy strong inference demand.

The company expects the third quarter of 2026 to represent the trough, with core gross margin guided to 38-40%, while core operating margin is expected to deteriorate to negative 25-23% from negative 16% in the second quarter of 2026. Although management expects margins to recover as higher-cost rented capacity is replaced by Cerebras-owned systems, near-term margin pressure likely tempered enthusiasm about the revenue outlook. For 2026, Cerebras now expects core gross margin between 41% and 43%, while operating margin is in the negative 19-17% range.

Stiff competition from companies like NVIDIA, Advanced Micro Devices and Intel also remains a concern. NVIDIA dominates the AI GPU market with its Blackwell, Hopper and DGX/NVL systems used for AI training and inference. Advanced Micro Devices’ MI300 and MI350 accelerator families are competing with CBRS in hyperscale AI infrastructure and enterprise AI clusters. Meanwhile, Intel’s Gaudi AI accelerators target enterprise AI training and inference as a lower-cost GPU alternative.

Cerebras shares are also trading at a premium, as suggested by the Value Score of D.

CBRS Stock: Here’s Why You Should HoldCerebras is benefiting from strong demand for fast inference, a $25.4 billion RPO, rapidly expanding manufacturing and data-center capacity, improving earnings estimates and partnerships that could broaden its customer base.

Moreover, Wall Street’s consensus price target implies roughly 104.13% upside from current levels.

Image Source: Zacks Investment Research

A US appeals court threw out on Friday an order allowing Tesla (TSLA.O) customers in California to pursue class action claims accusing the electric vehicle ​maker of misleading them about the capabilities of its full self-driving technology.

In ‌its ruling, a three-judge panel of the San Francisco-based 9th US Circuit Court of Appeals said there were too many individualized questions about what buyers actually saw before making a purchase, and so they ​could not sustain their lawsuit as a class action.

The appeals court decision is ​a win for now for Tesla, which had urged the appeals ⁠court to vacate orders by a California judge last year certifying three sets of ​classes. The ruling means the thousands of California buyers the lower court had grouped together ​cannot, for now, pursue their claims jointly in a single case.

The ruling is not on the merits of the plaintiffs' lawsuit alleging false advertising, and the case remains pending. The plaintiffs contend Tesla ​is misrepresenting its vehicles' hardware capabilities for full self-driving, convincing customers to pay extra ​money for software that they say does not work.

In a statement, the plaintiffs' lawyers said "we think the ‌panel ⁠did not fully appreciate the unique circumstances here, and the importance of the hardware statement to Tesla's marketing campaign."

Tesla did not immediately respond to a request for comment. Tesla has denied the plaintiffs' claims.

In the underlying case, US District Judge Rita Lin last ​year ruled that thousands of ​prospective buyers were ⁠likely exposed to Tesla's claim on its website that vehicles sold from October 2016 to the present contained hardware needed for full ​self-driving capability.

But the appeals court panel — Circuit Judges Ronald Gould, ​Jay Bybee ⁠and Daniel Bress — said the plaintiffs could not show that all class members had been exposed to the allegedly false statement.

The US Chamber of Commerce filed a court brief in ⁠support of ​Tesla and urged the appeals court to strike ​the class certification orders. The business advocate said the underlying ruling "threatens to substantially increase the costs to businesses ​and consumers of overbroad and meritless class proceedings."

, /PRNewswire/ -- Bank of America Corporation today announced the Board of Directors has authorized regular cash dividends on the outstanding shares or depositary shares of the following series of preferred stock: 

Series of Preferred Stock

Dividend per Share
or Depositary Share1

Record Date

Payment Date

Floating Rate Non-Cumulative Preferred Stock, Series E

$0.27806

October 30

November 16

Floating Rate Non-Cumulative Preferred Stock, Series F

$1,151.69600

November 30

December 15

Adjustable Rate Non-Cumulative Preferred Stock, Series G

$1,151.69600

November 30

December 15

Floating Rate Non-Cumulative Preferred Stock, Series 1

$0.29867

November 15

November 30

Floating Rate Non-Cumulative Preferred Stock, Series 2

$0.29892

November 15

November 30

Floating Rate Non-Cumulative Preferred Stock, Series 4

$0.30531

November 15

November 30

Floating Rate Non-Cumulative Preferred Stock, Series 5

$0.28761

November 1

November 23

6.000% Non-Cumulative Preferred Stock, Series GG

$0.3750000

November 1

November 16

5.375% Non-Cumulative Preferred Stock, Series KK

$0.3359375

December 1

December 28

5.000% Non-Cumulative Preferred Stock, Series LL

$0.3125000

December 1

December 17

4.250% Non-Cumulative Preferred Stock, Series QQ

$0.2656250

November 1

November 17

4.750% Non-Cumulative Preferred Stock, Series SS

$0.2968750

November 1

November 17

1 Each series of preferred stock, other than Series F and Series G, is represented by depositary shares.

Bank of America

Bank of America is one of the world's leading financial institutions, serving individual consumers, small and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving more than 69 million clients with approximately 3,500 retail financial centers, approximately 15,000 ATMs (automated teller machines) and award-winning digital banking with approximately 60 million verified digital users. Bank of America is a global leader in wealth management, corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. As the #1 small business lender in the United States (FDIC), Bank of America offers industry-leading support to approximately 4 million small business households through a suite of innovative, easy-to-use online products and services. The company serves clients through operations across the United States, its territories and more than 35 countries and/or jurisdictions. Bank of America Corporation stock (NYSE: BAC) is listed on the New York Stock Exchange.

Investors may contact

Lee McEntire, Bank of America
Phone: 1.980.388.6780
[email protected]

Jonathan G. Blum, Bank of America (Fixed Income)
Phone: 1.212.449.3112
[email protected]

Reporters may contact

Jocelyn Seidenfeld, Bank of America
Phone: 1.646.743.3356
[email protected]

SOURCE Bank of America Corporation

Also from this source

Last week, drugmaker Pfizer (PFE +0.48%) declared a $0.43 fourth-quarter dividend, its 352nd consecutive quarterly dividend. The forward annual dividend, therefore, is $1.72 per share, which represents a handsome 5.9% yield. Consider that the current average S&P 500 dividend yield is around 1%, and you'll see how attractive Pfizer's yield is.

But is Pfizer's dividend safe? It's something every income investor absolutely needs to know, because a company's share price typically declines after a dividend cut, for two primary reasons. One, income investors often sell the stock to seek income elsewhere. And two, investors more broadly view a dividend cut as a flashing red warning signal that a company is facing financial stress and weak cash flow.

And Pfizer did cut its dividend in half back in 2009 during the great financial crisis, when many companies were forced to slash their payouts. But since 2010, the company has raised its dividend every year. That's impressive. But is it sustainable?

Patent cliffs loom for Pfizer Like many other drugmakers, Pfizer is facing some significant patent cliffs. Its blood-thinner drug, Eliquis, and its autoimmune disease drug, Xeljanz, lose U.S. patent exclusivity this year. Ibrance, a breast cancer drug, and Xtandi, a prostate cancer drug, will lose their exclusivity next year.

So, Pfizer has to continue to fill its pipeline with potential new drugs. That pipeline leans heavily on new cancer drugs, and it has been expanding that with development programs to treat breast, prostate, bladder, and lung cancers.

Image source: Getty Images.

Fortunately, the company has a robust product portfolio that should keep revenue and cash flow healthy until new drugs are approved and launched. That includes migraine drug Nurtec, which saw 18% growth in the second quarter, and oncology drugs Lorbrena (37% growth) and Padcev (23% growth). Plus, free cash flow, which is needed to pay dividends, has totaled some $11 billion over the past four quarters, more than $1 billion above its dividend payments.

Management has reiterated that, as part of its capital allocation strategy, it is committed to maintaining, and over the longer term, growing the dividend.

Investors are cautiously optimistic: They've bid the stock up more than 17% year this year, which means it has outperformed the S&P 500 index by more than four percentage points. The stock has climbed about 19% over the past 52 weeks.

PFE Pfizer$29.58+$0.14 (+0.48%)

NYSE · As of 4:00 PM ET 10/16/26

So, if you want a high-yielding drug stock, Pfizer could be a good choice. But you have to have confidence that it can replace patent-cliff drugs with new pipeline drugs to keep cash flow healthy enough to pay its juicy dividend.

Palantir stock has suffered a big reversal, wiping out some of the gains made since June when it bottomed at $106.5. It dropped to $186.7, down by 12.75% from its highest point this year. Still, analysts are optimistic about the company, citing its strong fundamentals and revenue growth.

The ongoing PLTR stock sell-off has coincided with that of most software companies. Salesforce dropped to $241.4, down by 10% from its highest point in September. Other top software companies like Palo Alto Networks, Twilio, Okta, Fastly, and SentinelOne were among the top laggards.

One reason for the ongoing Palantir stock retreat is the upcoming midterm elections, where Democrats are set to win the House of Representatives and, potentially, the Senate. 

Analysts predict that a win by Democrats will lead to some major investigations on companies that have helped the administration on key issues. Palantir will be targeted for its role in helping the administration in border issues. It is unclear whether these investigations will impact its revenue and profitability growth.

Still, on the positive side, analysts are highly bullish on PLTR stock, citing its strong revenue and profitability growth. On Thursday, Mizuho analysts boosted the target from $215 to $245. Two days before that, Baird analysts set the target price at $250, while Barclays initiated with a target of $265. Other analysts who have maintained a bullish outlook for the stock are from Goldman Sachs, Raymond James, and UBS.

Most of these analysts are citing the company’s revenue and profitability growth. The most recent results showed that Palantir’s business continued doing well in the second quarter, driven by corporate and government orders.

American companies are increasingly turning to Palantir’s solutions, with the revenue rising by 149%. Their remaining deal value jumped to $6.24 billion, with more firms embracing its AIP solution. 

In total, Palantir’s revenue rose 93% YoY to $1.93 billion, while the adjusted income from operations rose to $1.19 billion. The management expects that this revenue growth will continue in the foreseeable future. 

Its third-quarter revenue is expected to be between $2.16 billion and $2.164 billion, much higher than the $1.18 billion it made last year.

READ MORE: Palantir stock is surging: will it retest its all-time high or reverse?

Palantir’s key valuation multiple, known as the Rule of 40, shows that it is highly undervalued. This multiple is calculated by adding a company’s revenue growth with its margins. In this case, adding the two gives PLTR a multiple of 155%, one of the highest in the US.

Traditional metrics, however, show that it is highly overvalued. It has a forward price-to-earnings ratio of 123, much higher than the sector median of 21.8. This multiple is much higher than other software companies like Microsoft, Salesforce, and Okta.

PLTR stock chart | Source: TradingView

The weekly chart shows that the PLTR stock rebounded from $106 in June to a high of $212 in this month. Its highest point was notable because it coincided with the highest point in November last year. It has also formed a bearish engulfing pattern, where a big bearish candle covers a bullish candle fully.

Therefore, the stock will likely retreat further, potentially to $160, and then resume the upward trend. If this happens, the stock will likely jump to $250.

Philip Morris just handed shareholders its biggest dividend jump in years, but a $43 billion debt load and a yield compressed by a scorching rally raise real questions about how long this pace can last.

Philip Morris International (NYSE:PM | PM Price Prediction) declared a quarterly dividend of $1.60 on Sept. 18, 2026. That is up from $1.47, a raise of 8.8%, and it lifts the annualized rate to $6.40. With shares at $204.54, the yield works out to about 3.1%. The yield has been contracted by the rally: the stock is up 30.83% year to date. Income investors now want to know whether PM’s cash engine can keep paying for increases like this one.

A Raise Streak Going Back to 2008 PM paid $0.46 per quarter in June 2008, just after its spin-off, and has raised the payout every year since. The recent steps were $1.20, $1.25, $1.27, $1.30, $1.35, $1.47, and now $1.60. The last two increases were bigger than anything PM paid out from 2019 through 2024. On the second-quarter call, then-CFO Emmanuel Babeau repeated the policy:

“We also remain a highly cash-generating business with an unwavering commitment to our progressive dividend policy and to returning value to shareholders.”

Coverage Math Income Investors Need Management raised its 2026 adjusted EPS guidance to $8.26 to $8.41. The $6.40 dividend takes up roughly 76% to 77% of that range. For 2025, operating cash flow of $12.233 billion minus $1.569 billion in capex left $10.664 billion of free cash flow. Dividends of $8.624 billion used about 81% of it.

The 2026 numbers point higher. PM is guiding to about $13.5 billion of operating cash flow and $1.4 to $1.6 billion of capex, with no buybacks planned. Babeau said:

“We continue to expect operating cash flow generation of around $13.5 billion, providing further flexibility to support both investment and continued attractive shareholder return.”

Smoke-Free Products Drive Future Raises Second-quarter revenue rose 10.4% to $11.19 billion. Adjusted EPS came in at $2.20, beating the $2.05 consensus. International smoke-free revenue grew 14.2%, and VEEV sales rose 55.1%. On June 30, the FDA granted modified-risk authorization to 20 ZYN versions. CEO Jacek Olczak said:

“Our global smoke-free portfolio is outgrowing the industry by a clear margin, driving positive total volumes, strong top-line growth and impressive margin expansion.”

Debt and Currency Can Slow the Pace Net debt stands at $43.1 billion, or 2.35x adjusted EBITDA. Management is aiming to get that close to 2.0x by year-end. Shareholders’ equity is negative at -$6.657 billion. Currency moves cut both ways. Exchange rates should add about 15 cents to full-year EPS, but the third-quarter outlook includes an 8-cent hit. Management also called continued dollar strength an uncertainty.

How PM Stacks Up Against Altria and BAT Altria Group (NYSE:MO) yields 5.93%. Its $4.24 dividend takes up about 87% of trailing GAAP EPS, and quarterly revenue grew only 1.2%. British American Tobacco (NYSE:BTI) yields 5.76% with a payout near 62%, but its revenue grew just 1.4%. PM pays the lowest yield of the three. It is also the only one growing its top line at a double-digit pace.

Verdict for Income Investors PM can keep raising its dividend. Earnings and free cash flow both cover the payout, smoke-free sales are growing at double-digit rates, and debt is coming down. Today’s buyers get a smaller starting yield than Altria or BAT in exchange for faster dividend growth. The appeal for income holders is a check that keeps rose without ever having to sell a share, which is the whole point of our free dividend ladder guide. Over the next few quarters, track whether net debt reaches the 2.0x target, how much the U.S. ZYN push costs, and where the dollar goes.

Contact [email protected] for any questions or corrections.

Eli Lilly's (LLY +0.43%) Zepbound, an anti-obesity medicine, was first approved in the U.S. in 2023. It has become one of the company's main growth drivers ever since and is now the top-selling drug in the chronic weight management landscape. Zepbound could remain one of the most important therapies in Eli Lilly's arsenal, given that the weight-loss market is growing rapidly. However, the drugmaker has several other medicines that could help power its next era of growth. Let's consider three of them.

Image source: The Motley Fool.

1. Foundayo
Foundayo is an oral GLP-1 medicine approved for weight loss. It first earned approval in the U.S. in April and has been fairly successful since. What's important about Foundayo is that it isn't just cannibalizing Zepbound's sales. Earlier this year, Eli Lilly noted that 80% of prescriptions for Foundayo were for patients who had never taken GLP-1 medicines before.

That makes sense. Zepbound is administered once weekly via subcutaneous injection. Some patients simply dislike needles. It also has storage requirements that, while not overly stringent, can be inconvenient for some patients, especially those who travel regularly. These factors likely helped Eli Lilly attract a new audience with Foundayo.

True, the medicine is trailing the Wegovy pill in the oral weight loss market. But Foundayo could gain significant traction over the medium term. Here are two reasons why. First, it can be taken at any time of day without food or water restrictions. By contrast, oral Wegovy is taken first thing in the morning on an empty stomach.

Second, and perhaps more importantly, Foundayo will likely earn important label expansions, including in diabetes, obstructive sleep apnea, and several other indications. These could help boost the medicine's sales over the next few years.

2. Onswik
Eli Lilly earned approval for Onswik, a diabetes medicine, in September. Onswik is a once-weekly basal insulin injection which, in clinical trials, showed efficacy comparable to that of daily insulin medicines. Of course, Onswik is much more convenient since it significantly reduces the number of doses per year. So, it could attract a decent number of patients.

Onswik isn't the first once-weekly insulin medicine to earn approval. That was Novo Nordisk's (NVO -0.99%) Awiqli, which earned approval in the U.S. in March. Still, the launch of Onswik should strengthen Eli Lilly's already strong diabetes portfolio.

$1,257.03+$5.42 (+0.43%)

NYSE · As of 4:00 PM ET 10/16/26

3. Retatrutide
Retatrutide is the only one of Eli Lilly's next-gen drugs discussed here that has yet to earn approval. However, it could be the most promising. Retatrutide is an investigational weight-loss medicine that mimics the actions of three gut hormones: GLP-1, GIP, and glucagon. Here's why that's significant. Zepbound's market-leading efficacy is partly attributed to its ability to mimic two gut hormones, GLP-1 and GIP, whereas its main competitor, Wegovy, mimics only GLP-1.

But retatrutide goes one step further than Zepbound, which could, in theory, lead to even stronger efficacy. The data so far appear to support that theory. In one Phase 3 study, retatrutide led to an average weight loss of up to 28.3% over 80 weeks.

It has also shown tremendous promise in helping patients with diabetes lose weight (which is typically harder for them), as well as in other indications, such as obstructive sleep apnea. Retatrutide shouldn't simply cannibalize Zepbound's sales either -- it could attract newer patients, including those with very high BMIs (body mass indexes) who have had trouble losing weight even with the currently available options. Retatrutide could become one of Eli Lilly's key growth drivers. The pharmaceutical company plans to submit regulatory applications for the drug in the first quarter of 2027.

Buy and forget
This is not an exhaustive list of Eli Lilly's promising drugs and pipeline candidates. Others, such as eloralintide, an investigational drug for weight loss, Kisunla, a medicine approved for Alzheimer's disease (AD), and remternetug, which is being developed for AD, look promising as well. Eli Lilly will face more competition in the weight loss market in the coming years, but the company's pipeline across weight loss, diabetes, and other areas could allow it to remain one of the leaders in its core market while making significant progress in others. That's why, even though it has crushed broader equities in recent years, Eli Lilly remains one of the top healthcare stocks to buy.

by Lisa Stiffler on

Inrix co-founder and CEO Bryan Mistele above rush-hour traffic on Interstate 5 in Seattle in 2011. After more than two decades of turning traffic data into a business, Inrix has agreed to sell substantially all of its assets to Arity, a subsidiary of Allstate. (GeekWire File Photo / Annie Laurie Malarkey) Inrix, the Bellevue, Wash.-based traffic data company that spun out of Microsoft in 2004 and became one of the Seattle region’s longest-running independent tech companies, has agreed to sell substantially all of its assets to Arity, the mobility data subsidiary of insurance giant Allstate.

The deal, announced Friday, would end Inrix‘s 22-year run as a standalone company. Inrix has raised more than $288 million and flirted with an IPO multiple times over its lifetime. Terms were not disclosed. The companies expect the acquisition to close later this year.

Founded in 2016, Chicago-based Arity analyzes driving behavior for insurers, marketers and public-sector customers. It says it has amassed more than 3 trillion miles of driving data. The acquisition would pair that information with Inrix’s analytics on traffic, road conditions and transportation networks.

“By combining Arity’s predictive insights on driving behavior and risk with Inrix’s transportation intelligence and mobility analytics, we will be uniquely positioned to deliver more robust intelligence and insights into how people, vehicles, goods, and roads interact,” Gary Hallgren, president of Arity, said in a statement.

While the companies are touting the benefits of combining their data and analytics, Arity’s data practices have faced legal scrutiny. In January 2025, Texas sued Allstate and Arity, alleging they collected and sold consumers’ driving and location data without adequate consent. Responding to a separate consumer privacy lawsuit in March, Allstate told Reuters that users receive clear notice and explicitly opt in to sharing their driving data.

The proposed acquisition charts an alternate course to Inrix’s earlier plans for going public. In 2012, Inrix hired Goldman Sachs and JPMorgan Chase with an eye toward a 2013 IPO that was expected to raise up to $100 million. The company looked to go public again in 2022 but backed out amid economic uncertainty stemming from Russia’s invasion of Ukraine and other factors.

“We were about two weeks away from filing our documents with the SEC,” Inrix CEO Bryan Mistele said in an August 2022 GeekWire story. “We’re on standby right now, waiting to see when the markets and economy improve, in which case we’ll take another run at it.”

Inrix serves corporate, automotive, technology and public-sector customers including Amazon, IBM, General Motors, Windermere Real Estate and state departments of transportation.

The company got its start selling traffic and transportation-related data. In recent years, it moved beyond supplying raw traffic data into subscription software that helps customers interpret it, including tools for traffic-signal timing, road safety and retail site selection.

Recent public releases include its first Parking Scorecard, which ranks the availability and cost of parking in major cities in the U.S. and Europe.

Inrix has about 277 employees, based on LinkedIn data. The companies did not say whether all of them would remain or whether Inrix would keep its Bellevue headquarters.

The story will be updated with additional information as it becomes available.

Key Takeaways Molina Healthcare's Q3 earnings are projected to plunge 60.9%, with revenues expected to decline 4.8%.MOH's premium revenues are expected to fall 4.9%, while its medical care ratio is projected to rise to 93%.Molina Healthcare's membership is forecast to drop 12.7%, led by a 63% plunge in Marketplace enrollment. Molina Healthcare, Inc. (MOH - Free Report) is set to report its third-quarter 2026 results on Oct. 21, 2026, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at 72 cents per shareon revenues of $10.93 billion.

The third-quarter earnings estimate witnessed two downward revisions and no upward revisions over the past 60 days. The bottom-line projection indicates a year-over-year decline of 60.9%. Also, the Zacks Consensus Estimate for quarterly revenues implies a year-over-year decrease of 4.8%.

Image Source: Zacks Investment Research

For 2026, the Zacks Consensus Estimate for Molina Healthcare’s revenues is pegged at $44.47 billion, implying a decline of 2.1% year over year. The consensus mark for 2026 EPS is pegged at $5.28, indicating a 52.1% year-over-year decrease.

Molina Healthcare’searnings beat the consensus estimate in two of the trailing four quarters and missed twice, with the average surprise being negative 183.3%. This is depicted in the figure below.

Q3 Earnings Whispers for MOHOur proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here.

MOH currently has an Earnings ESP of -3.30% and a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

What’s Shaping MOH’s Q3 Results?The Zacks Consensus Estimate projects premium revenues to decline 4.9% year over year from $10.84 billion, as lower revenues from Medicare and Marketplace are expected to outweigh gains from Medicaid. Investment income is also expected to fall 7% to $100.4 million. In contrast, premium tax revenues are forecast to rise 0.6% to $509 million.

Profitability could face additional pressure, with the consensus estimate for the consolidated medical care ratio (MCR) at 93%, up from 92.6% in the year-ago quarter. A higher MCR means the company is expected to spend more on medical care relative to its premium revenue.

Membership trends also point to a weaker quarter. The Zacks Consensus Estimate calls for total membership to decline 12.7% year over year. Medicaid membership is expected to fall nearly 5%, while Medicare and Marketplace membership could drop 14.6% and 63%, respectively.

With premium revenues, investment income and membership all expected to decline, alongside a higher MCR, the company faces several headwinds heading into the third-quarter report. These pressures could weigh on earnings and make an earnings beat harder to achieve.

Stocks That Warrant a LookWhile an earnings beat looks uncertain for Molina Healthcare, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:

Aveanna Healthcare Holdings Inc. (AVAH - Free Report) has an Earnings ESP of +3.28% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Aveanna Healthcare’s bottom line for the to-be-reported quarter of 20 cents indicates 33.3% year-over-year growth. It has witnessed one upward revision against no downward movement over the past 60 days. The consensus mark for revenues predicts a 9.9% increase from a year ago.

CVS Health Corporation (CVS - Free Report) has an Earnings ESP of +0.79% and a Zacks Rank of 3.

The Zacks Consensus Estimate for CVS Health’s bottom line for the to-be-reported quarter indicates a 1.3% increase from a year ago. The company’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 20.5%. The consensus estimate for CVS’ revenues is pegged at $105.04 billion, signaling a 2.1% increase.

Acadia Healthcare Company, Inc. (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank of 3.

The Zacks Consensus Estimate for Acadia Healthcare’s bottom line for the to-be-reported quarter is pegged at 46 cents per share, which remained stable over the past week. Its earnings beat estimates in each of the past four quarters, with an average surprise of 47%. ACHC’s revenues for the to-be-reported quarter are pegged at $869.26 million, a 2.1% increase from the year-ago period.

8 hours ago

Modular blockchain project Celestia has announced the launch of Eden, a high-performance EVM chain built on Celestia. Celestia says Eden will act as an experimental sandbox for "Agentic Commerce", used to test the behavior and infrastructure needs of AI agents when conducting on-chain autonomous payments, transactions, and model calls. Celestia notes that as AI agents start engaging in more frequent on-chain transactions, market demand for block space, real-time settlement, and low-friction payments will continue to rise. Eden will help teams observe what transaction environment agents need, how they manage funds, and how their on-chain activities will impact network design. Eden’s first experimental project is Botfun, which is currently in closed beta. Per Celestia, participating agents can issue their own tokens and trade around narratives generated by other agents; each model inference call is paid on-chain via x402. Celestia states this experiment briefly pushed Eden to become one of the largest x402 networks by transaction volume. Technically, Eden is an EVM-compatible chain supporting atomic batch transactions, application-sponsored gas payments, and larger smart contract deployments, with its native gas token being TIA. These designs will reduce signature and fee friction when agents execute consecutive payments, swaps, and interactions.

Scan the QR code

Download APP

The board of directors of MGE Energy, Inc. (Nasdaq: MGEE), today declared the regular quarterly dividend of $0.5083 per share on the outstanding shares of the company's common stock, payable December 15, 2026, to shareholders of record at the close of business December 1, 2026.

MGE Energy has increased its dividend annually for the past 51 years and has paid cash dividends for more than 115 years.

About MGE Energy

MGE Energy is a public utility holding company. Its principal subsidiary, Madison Gas and Electric, generates and distributes electricity to 170,000 customers in Dane County, Wis., and purchases and distributes natural gas to 180,000 customers in seven south-central and western Wisconsin counties. MGE's roots in the Madison area date back more than 150 years.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261016538318/en/

Also check out: (Free Trial)

High Yield Dividend Stocks in Gurus' Portfolio Top dividend stocks of Warren Buffett Top dividend stocks of George Soros
Check the Warning Signs for

MGEE

now!

"TAO has probably the biggest compression in crypto right now," one popular X user stated.

The popular altcoin has surpassed $285 after posting a double-digit daily increase, sparking optimism that its rally could continue in the near term.

Some forecasts are highly bullish and even implausible (at least for now).

Just the Beginning? TAO has performed quite well today (October 16), largely because of the market’s overall resurgence, with Bitcoin (BTC) reclaiming $82,000 and Ethereum (ETH) rebounding to around $2,450.

On top of that, another catalyst tied directly to the asset’s ecosystem could be in play. Bittensor’s team revealed the release of Null Consensus, a major protocol update that expands subnet capacity from 256 to 2,500 participants.

“It introduces a new way to determine miner rewards, giving subnet owners an alternative to Yuma Consensus,” the announcement reads.

The update also introduces optional proof-of-work registration, letting miners join subnets without spending TAO upfront. Instead of paying a fee, they can now solve a computational challenge using their hardware.

“This opens the door for more miners, including autonomous AI agents, to join Bittensor using compute alone,” the team added.

The asset has drawn numerous bullish predictions lately, and the latest price increase prompted further commentary. X user Michael van de Poppe said he’s started to like TAO’s chart even more because he sees “a clear bullish structure.”

Lucky and Sjuul | AltCryptoGems also weighed in. The former recently envisioned a potential increase toward $350-$400 by the end of the year, while the latter claimed the price has been consolidating within a massive range since the summer of 2024 and that could ultimately give way to an “epic expansion,” assuming macro support levels continue to hold.

You may also like: ‘Buy Crypto’ Google Searches Hit Yearly Highs: Is Retail Coming Back? Altcoins Are Rallying, But Analyst Says Alt Season Has Yet to Begin Trump’s $5,000 Checks Could Send Billions Into Bitcoin and Crypto: But There’s a Catch For their part, Crypto Candy maintained that this is the last chance to buy the asset below $300, expecting a 10x explosion in the midterm.

The Crazy Bet X user Rob Greer recently made a much more bullish price prediction than the ones above. He projected that TAO’s market cap could skyrocket above $1 trillion by 2030, suggesting the asset’s valuation “is moving at the speed of BTC, but the innovation is moving at the speed of AI.”

For now, that scenario seems highly unlikely. The token’s market capitalization is currently below $3.3 billion, meaning it would need to gain over $30,000 to reach that level. On the other hand, the crypto market is known for defying expectations, so who knows what the future might bring.

Tags:

Ondo Finance’s dominance of the tokenized equities market has narrowed, with its share sliding from 56% to 26% between early January and the week of Oct. 5 as new entrants such as Binance and Robinhood attracted users and capital, according to new research from DWF Labs.

An early mover in institutional real-world asset tokenization, Ondo still led the market with about $1 billion in value during the period, while the sector’s total market value climbed 483% to $3.8 billion.

Binance’s bStocks, which recently hit $1 billion in assets under management, grew to $905 million and captured 24% of the tokenized stock market, the report reveals. Robinhood’s tokenized equities increased from $20 million following their July launch to $170 million.

Meanwhile, Securitize reached $290 million, accounting for 8% of the market, while xStocks grew from $187 million to $954 million and maintained a 25% share.

The report notes that Ethereum’s early lead in tokenized equities has weakened as issuers have expanded into competing networks. Its share declined from 50% at the start of the year to 22% in October, while BNB Chain increased from 9% to 32%.

Binance’s entry also strengthened BNB Chain, where CRCLb, SPCXb and MSTRb rank among the 10 largest tokenized equities. Avalanche, which had no market share at the start of the year, reached 9% after Securitize launched tokenized shares on the network in July.

On-chain activity jump 42-fold in 2026
On-chain activity in tokenized equities has increased sharply in 2026, with weekly transfer volume rising 41.8-fold from $420 million in early January to $17.5 billion in early October, according to the report.

Turnover climbed from 0.64 times to 4.6 times market capitalization, while weekly decentralized exchange (DEX) trading velocity rose from 0.07 times to 0.67 times market capitalization.

Trading peaked at about $7.3 billion in the week of Aug. 31, with Robinhood Chain accounting for approximately $5.4 billion, the report details.

Activity has also spread across more networks. Solana’s share of trading fell from 99.8% in January to 31% in October, while Robinhood Chain, BNB Chain and Base captured 26%, 25% and 18%, respectively.

Tokenized equities are also seeing increased use in decentralized finance (DeFi). Active total value locked (TVL) rose about 20-fold, from $15.5 million on Jan. 1 to $313 million on Oct. 15, compared with 5.8-fold growth in market capitalization between early January and early October. Deployed capital increased from approximately 2% to 8% of market capitalization.

Spot DEX pools held $77.9 million, followed by lending and borrowing markets at $51.3 million, Saturn at $50.9 million, Figure Markets Exchange at $48.9 million and Pendle yield markets at $42.6 million. The top 10 protocols accounted for 89% of total deployed value.

Despite rising trading activity and DeFi adoption, tokenized equities are still small relative to traditional equity markets, which DWF Labs estimates at $75 trillion in the US and $150 trillion globally. The gap leaves enormous potential for further growth as on-chain trading and DeFi use develop.

Disclosure: This article was edited by Vivian Nguyen. For more information on how we create and review content, see our Editorial Policy.